PB006

polpharma biosimilar natalizumab · Polpharma Biologics S.A.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PB006, covering 2023-07-03 to 2023-07-03. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® [Phase 3]